Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name Emibetuzumab
Trade Name
Synonyms LY2875358
Drug Descriptions

Emibetuzumab (LY2875358) is MET-targeted antibody, which inhibits binding of the MET ligand HGF and promotes internalization and downregulation of MET, resulting in decreased HGF-dependent and HGF-independent signaling and potentially leading to decreased growth of MET-expressing tumors (PMID: 27803065, PMID: 25231402, PMID: 31622732).

DrugClasses MET Antibody 29 MET Inhibitor 59
CAS Registry Number 1365287-97-3
NCIT ID C95732


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Emibetuzumab Emibetuzumab 0 2
Emibetuzumab + Erlotinib Emibetuzumab Erlotinib 0 2
Emibetuzumab + Ramucirumab Emibetuzumab Ramucirumab 0 1
Emibetuzumab + Trametinib Emibetuzumab Trametinib 0 1

Additional content available in CKB BOOST